U.S. markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.27
    +2.15 (+2.62%)
     
  • Gold

    1,817.30
    -4.10 (-0.23%)
     
  • Silver

    22.99
    -0.17 (-0.74%)
     
  • EUR/USD

    1.1416
    -0.0044 (-0.39%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • GBP/USD

    1.3680
    -0.0030 (-0.22%)
     
  • USD/JPY

    114.2000
    +0.0200 (+0.02%)
     
  • BTC-USD

    42,980.33
    -433.99 (-1.00%)
     
  • CMC Crypto 200

    1,037.76
    +12.03 (+1.17%)
     
  • FTSE 100

    7,542.95
    -20.90 (-0.28%)
     
  • Nikkei 225

    28,124.28
    -364.82 (-1.28%)
     

GlaxoSmithKline Drops Research On Otilimab In COVID-19

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • GlaxoSmithKline Plc (NYSE: GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years old.

  • The Company decided because their already-approved monoclonal antibody Xevudy “plays an important role as a treatment for mild-to-moderate COVID-19 in high-risk adult and pediatric patients,” according to a company statement.

  • In February, GSK revealed that a single dose of otilimab failed to improve the likelihood of being alive and free of respiratory failure 28 days later in patients with severe COVID-19-related pulmonary disease.

  • While GSK is stopping work on COVID-19, it is continuing to study otilimab in rheumatoid arthritis.

  • A phase 3 clinical trial in the indication is scheduled to deliver data in 2H of 2022.

  • Xevudy (sotrovimab) is the anti-SARS-CoV-2 antibody GSK is developing with Vir Biotechnology Inc (NASDAQ: VIR).

  • Related: Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug.

  • Price Action: GSK shares are up 0.39% at $40.34 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.